Tumors
154
6
8
103
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
25 trials with published results (16%)
Research Maturity
103 completed trials (67% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.2%
25 terminated out of 154 trials
80.5%
-6.0% vs benchmark
5%
7 trials in Phase 3/4
24%
25 of 103 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 103 completed trials
Clinical Trials (154)
Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors
Phase 1 Study of E7090 in Subjects With Solid Tumor
HP Pyruvate MRI in Cancers
POWER UP: Participating Online While Exercising to Recover Using Play
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection
Perioperative Risk Study
CDK4/6 Tumor, Abemaciclib, Paclitaxel
A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Cohort of Tumors With POLE/D1 Mutation
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Point of Care 3D Ultrasound for Various Applications: A Pilot Study
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
The Drug Rediscovery Protocol (DRUP Trial)
A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
A Phase I Study of PLX038 in Patients With Advanced Solid Tumors